^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IPN60340

    i
    Other names: IPN60340, ICT01, IV ICT01, humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody, ICT 01, ICT-01, IV ICT-01, IV ICT 01, IPN 60340, IPN-60340
    Associations

    News

    Trials
    Company:
    ImCheck Therap, Ipsen
    Drug class:
    γδ TCR modulator, CD277 agonist
    Related drugs:
    Associations

    News

    Trials
    7d
    EVICTION 3: A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=450, Not yet recruiting, Ipsen
    New P2/3 trial
    |
    Venclexta (venetoclax) • azacitidine • IPN60340
    4ms
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial primary completion date: Oct 2026 --> Oct 2025
    Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • IPN60340
    6ms
    EVICTION-2: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=56, Completed, ImCheck Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin) • IPN60340
    6ms
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • IPN60340
    1year
    EVICTION-2: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, ImCheck Therapeutics | Trial primary completion date: Apr 2025 --> Sep 2025
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin) • IPN60340
    1year
    EVICTION: First-in-Human Study of ICT01 in Patients with Advanced Cancer (clinicaltrials.gov)
    P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Recruiting --> Active, not recruiting | N=150 --> 292 | Trial primary completion date: Jun 2025 --> Sep 2025
    Enrollment closed • Enrollment change • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • IPN60340
    1year
    EVICTION-2: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, ImCheck Therapeutics | Recruiting --> Active, not recruiting | N=100 --> 56
    Enrollment closed • Enrollment change
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin) • IPN60340
    almost2years
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=150, Recruiting, ImCheck Therapeutics | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    Keytruda (pembrolizumab) • IPN60340
    almost2years
    EVICTION-2: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=100, Recruiting, ImCheck Therapeutics | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin) • IPN60340
    over2years
    Evaluation of ICT01, a γ9δ2 T Cell-Activating Monoclonal Antibody, Combined with Venetoclax and Azacitidine in 1L AML (EVICTION Study) (ASH 2023)
    ICT01, a first-in-class anti-BTN3A mAb activating γ9δ2 T cells, completed Phase 1 testing in relapsed/refractory (r/r) solid tumors as monotherapy and in combination with pembrolizumab, and as monotherapy in r/r AML and lymphoma (EVICTION-NCT04243499). Encouraging results obtained in the EVICTION Phase 1 trial and preclinical demonstration of the benefit of using ICT01 plus VEN/AZA allowed the initiation of a Phase 2a expansion cohort to evaluate the clinical benefit of this combination in 1L AML patients.
    PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IL4 (Interleukin 4)
    |
    Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine • IPN60340
    almost3years
    EVICTION-2 Clinical Trial: Combining ImmunoCytokines and ICT1 to Expand Endogenous Gamma9Delta2 T Cells (IO-SUMMIT EUROPE 2023)
    However, the pharmacodynamic effects of ICT01 are dependent on the number of circulating gamma9d2 T cells, which is low in most advanced cancer patients. Preclinical studies showed that ICT01 plus IL-2 induces selective expansion of gamma9d2 T cells with minimal Treg expansion supporting an ongoing Phase I/IIa (EVICTION-2) in patients with advanced-stage solid tumors.
    Clinical
    |
    IL2 (Interleukin 2)
    |
    IPN60340
    over3years
    EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=150, Recruiting, ImCheck Therapeutics | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Mar 2024
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    CD69 (CD69 Molecule)
    |
    Keytruda (pembrolizumab) • IPN60340